2025 Annual Meeting of the International Society for Pharmacoepidemiology (ISPE)
AUGUST 22–26, 2025 | WASHINGTON DC, USA
Chart the Next Frontier in Pharmacoepidemiology with TriNetX at ISPE 2025
Book a Meeting
Posters
The pharmacoepidemiology landscape is evolving — faster, more complex, and globally interconnected than ever before. With the rising demand for high-quality real-world evidence (RWE), researchers face increasing pressure to innovate, scale, and deliver impactful insights that influence patient outcomes.
At the 2025 ISPE Annual Meeting, TriNetX is your partner in navigating these challenges. We help pharmacoepidemiologists break through barriers, from gaining access to diverse global data to accelerating timelines for regulatory-grade studies and enhancing consistency in real-world safety and effectiveness evaluations.
TriNetX is not just a platform, it’s a guide for uncovering new frontiers in research. Powered by one of the world’s largest RWE networks and an ecosystem of trusted global collaborators, TriNetX helps research teams chart a course for discovery: faster, smarter, and with greater clarity.
Inside the Evidence: TriNetX Poster Presentations
Step into a space where data becomes discovery.
Our poster presentations this year spotlight how the TriNetX platform, data, and analytics are advancing drug safety, effectiveness, and regulatory-grade study design. From global data access to AI-driven insights, each study showcases how real-world research can drive meaningful impact across the product lifecycle.
Explore the full lineup and see how your peers are using TriNetX to unlock smarter, faster breakthroughs.
Why Meet with TriNetX?
You’re here to lead the way, and TriNetX is here to empower you.
With TriNetX, you’ll gain access to:
- Unmatched global data spanning diverse regions, populations, and care settings, providing unparalleled insights into pharmacoepidemiology and drug safety.
- Accelerated study design and execution to meet the fast-paced demands of regulatory agencies, ensuring your studies are both efficient and compliant.
- A trusted partner with a proven track record, recognized by top institutions and regulatory agencies worldwide for our contributions to observational research and RWE.
Let’s Explore What’s Next. Together
Are you ready to take your pharmacoepidemiology research to new heights? Join us in Washington DC to explore the future of real-world evidence, smarter, faster, and more boldly than ever before.
Our World-Renowned Experts
Jeff Brown
Chief Scientific Officer
K. Arnold Chan, MD, ScD, FISPE
Senior Vice-President, CSO Office
E. Susan Amirian, PhD
VP, Research and Data Solutions
Andreas Weber
Senior Vice-President, Oncology
See all TriNetX contributions at ISPE
Explore groundbreaking posters from TriNetX experts and TriNetX Real-World Data Networks, showcasing pioneering advancements in real-world data analytics. Discover how we’re reshaping the future of healthcare outcomes through insightful research and transformative technologies. Join us as we redefine possibilities in global health at the 2025 ISPE Annual Meeting.
Age and multimodal safety assessments: limitations of spontaneous reports data and the importance of advancing age-based risk stratification capabilities in real world data
Presenting author: Darmendra Ramcharran, PhD, MPH, Sr Director, Safety Innovation & Analytics, GSK
Co-authors: Kaylen Brzozowski, MPH, TriNetX
Greg Powell, GSK,
Olivia Mahaux, GSK
Andrew Bate, GSK
Date: Sunday 24 August
Time: 12:00pm – 1:30pm ET
Where to find us: Poster Session A
Trends in Outpatient Antibiotic Prescribing in the United States using Real World Data from 2020 to 2024
Presenting author: Kaylen Brzozowski, MPH
Co-authors: Eric Young, PharmD, PhD
Date: Tuesday 26 August
Time: 12:00pm – 1:30pm ET
Where to find us: Poster Session C
Characterization of Adult Patients with Cystic Fibrosis in the TriNetX Linked EHR + Claims Network
Presenting author: Amanda M. Moore
Co-authors: Ellen Stein, E. Susan Amirian
Date: Tuesday 26 August
Time: 12:00pm – 1:30pm ET
Where to find us: Poster Session C
TriNetX Publications for Pharmacoepidemiology
Delve into our archive of past publications to gain insights into the latest trends and advancements in pharmacoepidemiology. Each publication underscores our commitment to advancing the field and contributing valuable knowledge to the global healthcare community. From cutting-edge methodologies to real-world data analyses, publications using TriNetX are widely recognized for their quality and relevance.
A Sample of TriNetX Published Research
Real-World Effectiveness of Bebtelovimab Versus Nirmatrelvir/Ritonavir in Outpatients with COVID-19
Christopher G. Rowan, Russell M. Nichols, Neil Dhopeshwarkar, Jennifer M. Alyea, Baojin Zhu, Sengwee Toh, K. Arnold Chan & Elsie L. Grace Real-World Effectiveness of Bebtelovimab Versus Nirmatrelvir/Ritonavir in Outpatients with COVID-19. Pulm Ther 11, 55–67 (2025).
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of mild-to-moderate COVID-19 in multiple sclerosis: A retrospective cohort study
Jin H, Geiger C, Jessop N, Pedotti R, Raposo C, Whitley L, Brown JS, Muros-Le Rouzic E. Anti-SARS-CoV-2 monoclonal antibodies for the treatment of mild-to-moderate COVID-19 in multiple sclerosis: A retrospective cohort study. Mult Scler Relat Disord. 2023 Nov;79:104943. doi: 10.1016/j.msard.2023.104943. Epub 2023 Aug 23. PMID: 37716211.
Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3-4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study
Rowan CG, Agiro A, Chan KA, Colman E, White K, Desai P, Dwyer JP. Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3-4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study. Adv Ther. 2024 Jun;41(6):2381-2398. doi: 10.1007/s12325-024-02835-8. Epub 2024 Apr 30. PMID: 38687454; PMCID: PMC11133091.
Let’s Talk
Reserve your time with TriNetX experts live at ISPE 2025. Space is limited.
Our Mission is Our Promise
At TriNetX, our mission is to operate the world’s broadest federated network of real-world data in partnership with healthcare providers and apply intelligence that accelerates innovation across the healthcare ecosystem.
Access and Analyze Rich, Secure, Real-Time Data
TriNetX is a global network of healthcare organizations and life science companies, driving real-world research to accelerate the development of life-saving therapies.
From trial operations to evidence generation, we put you at the forefront of discovery.
Clinical Trial Design & Optimization
Datasets & Analytics
Non-US Oncology
Real-World Evidence Generation
Pharmacovigilance & Drug Safety
Events with TriNetX
Please complete the form below to request a meeting with the TriNetX team, and learn how you could become part of the connections improving human health across the world.
Jeffrey Brown
Chief Scientific Officer
Jeffrey Brown, PhD is an internationally recognized expert in the use of real-world data to support the evidentiary needs of regulatory agencies and medical product sponsors and an expert in the assessment of data quality of real-world data resources. Dr. Brown has more than 25 years of experience in research using real-world data, most recently as an Associate Professor in the Department of Population Medicine at Harvard Medical School and as a trusted consultant to numerous research groups and pharma companies. Dr. Brown holds a master’s degree in Economics from Tufts University and a PhD in Social Policy from Brandeis University.
E. Susan Amirian, PhD
VP, Research and Data Solutions
A seasoned MD Anderson-trained epidemiologist with over 15 years of observational research experience, Dr. Amirian has previously led teams on sponsored real-world research projects at small startups and a Fortune 10 company, where she drove impactful insights from real-world data. She also led the Public Health Portfolio at the Texas Policy Lab, Rice University, focusing on innovative public health initiatives. Before this, she was an Assistant Professor in the Division of Hematology-Oncology at Baylor College of Medicine and was the Associate Director of Data Quality at the Population Sciences Biorepository. Her expertise spans epidemiology, oncology, and data quality management, contributing significantly to advancing medical research and healthcare practices.
K. Arnold Chan, MD, ScD, FISPE
Senior Vice-President, CSO Office
K. Arnold Chan, MD, ScD, FISPE, is an internationally recognized epidemiologist with more than 30 years of global research experience in academia and the private sector, primarily in the post-marketing evaluation of pharmaceutical agents and vaccines. He has served on the Harvard School of Public Health and National Taiwan University faculty and was Chief Scientist of the epidemiology unit of a Fortune 10 company. Dr. Chan has authored or co-authored more than 150 peer-reviewed articles on pharmacoepidemiology and clinical epidemiology and co-edited a textbook on pharmacoepidemiology and therapeutic risk management.
Andreas Weber
Senior Vice-President, Oncology
Andreas brings a wealth of experience to the TriNetX team, following a distinguished 30-year career in the life sciences industry. Most recently, he served as the CEO of EvidentIQ, a leading provider of technology and data science solutions for clinical research. His career includes senior management roles at ERT/BioClinica and Oracle Health Sciences, where he built a 17-year sales and business development legacy.
As a senior executive with a proven track record in management and leadership, Andreas is known for his deep understanding of life sciences, spanning the entire industry continuum. His expertise encompasses pharmacovigilance, drug safety, regulatory affairs, and end-to-end eClinical processes, with a strong focus on business process optimization, outsourcing, and information technology.
Andreas’s career reflects a commitment to advancing the life sciences industry through strategic innovation and effective leadership, making him a valuable asset to TriNetX and a respected figure in European oncology research.
